by Administrators Qynapse | Nov 3, 2020 | News
Paris, France and Boston, MA, November 3rd, 2020 – QYNAPSE SAS, a medical technology company, will present results on QyPredict®, an AI prediction technology for patient selection in Alzheimer’s clinical trials, at the 13th Clinical Trials on Alzheimer’s Disease...
by Administrators Qynapse | Oct 13, 2020 | News
Acquisition of TRUE POSITIVE MEDICAL DEVICES by QYNAPSE • A strategic collaboration that covers 15 patents, including 9 issued in the U.S. and Canada • A unique technology alliance to improve clinical trials performance and personalize brain diseases management PARIS,...
by Administrators Qynapse | Sep 21, 2020 | News
Worldwide, 50 million people are living with Alzheimer’s and other dementias. By the year 2050, this number could grow to 100 million (1,2). This year, as the world faces the global COVID-19 health crisis, fragile people and especially patients suffering from...
by Administrators Qynapse | Sep 16, 2020 | News
Magnetic Resonance Imaging (MRI) of the brain plays a crucial role in the clinical assessment of Multiple Sclerosis (MS). The analysis of MRI markers is a key component for the disease diagnosis – and these markers are also employed to assess the disease stage,...
by Administrators Qynapse | Sep 7, 2020 | News
Qynapse is excited to participate in MSVirtual2020 to share and discuss innovative and cutting-edge research in the field of Multiple Sclerosis (MS). With more than 2 million people affected worldwide; MS is the leading cause of non-traumatic disability in young...
by Administrators Qynapse | Aug 31, 2020 | News
The world has been facing the COVID-19 global pandemic for several months now, yet new symptoms are still being discovered. According to a recent study, 45% of patients with severe manifestations of COVID-19 experience neurological damage and neurological symptoms...
